# RESIST-2: 2nd-line ART for HIV-2 Infection

> **NCT03394196** · NA · TERMINATED · sponsor: **University of Washington** · enrollment: 152 (actual)

## Conditions studied

- HIV-2 Infection

## Interventions

- **DIAGNOSTIC_TEST:** HIV-2 Genotypic Drug Resistance Testing using DBS
- **DRUG:** 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)
- **DRUG:** 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
- **DRUG:** 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)

## Key facts

- **NCT ID:** NCT03394196
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-04
- **Primary completion:** 2020-05-31
- **Final completion:** 2020-05-31
- **Target enrollment:** 152 (ACTUAL)
- **Why stopped:** COVID-19 and Funding
- **Last updated:** 2021-01-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03394196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03394196, "RESIST-2: 2nd-line ART for HIV-2 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03394196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*